Cell study finds CBG can amplify adenosine signalling at A3 receptors
Cannabinoids as Context-Dependent Modulators of the Adenosine A3 Receptors: Potential Orthosteric and Allosteric Mechanisms.
AI Summary
This abstract-based summary describes a laboratory study asking whether the cannabinoids CBD and CBG alter signalling by the human adenosine A3 receptor (A3R). Researchers used A3R-expressing cells and measured cAMP responses, comparing the cannabinoids alone and alongside adenosine. They also used receptor-blocking experiments and computational approaches including molecular docking and molecular-dynamics simulations. This was a cell-based and computational study, not a clinical trial in people.
Both cannabinoids reduced forskolin-stimulated cAMP accumulation in A3R-expressing cells, while this effect was absent in non-transfected cells and blocked by an A3R antagonist. CBG was more potent than CBD in this assay, with reported IC50 values of 0.130 µM and 1.05 µM, respectively, although their maximum inhibitory effects were similar. When combined with adenosine, 100 nM CBG increased adenosine’s apparent potency by approximately 138-fold and also increased its maximum inhibitory response; CBD produced a smaller shift. The findings suggest that CBG may enhance adenosine activity at A3R through a possible allosteric or occupancy-dependent mechanism. However, direct binding studies, additional signalling tests, receptor-subtype comparisons, and structural studies are still needed, so this work cannot establish a therapeutic benefit or predict effects in humans.
💡 Key Findings
📄
Original Abstract
Related Research
Similar Studies
More CBD research papers you might find interesting.
A lab method measures 17 cannabinoids across five hemp product types
CBD showed limited adaptive-functioning differences versus placebo in boys…
NMR profiling finds THC predominates in Moroccan beldia extracts
Explore More Research
Stay informed about the latest cannabis science.